Investigating the role of dopaminergic and serotonergic candidate genes in obsessive-compulsive disorder

European Neuropsychopharmacology

Volumn 13, Issue 2, 2003, Pages 93-98

  Hemmings, Sîan M J ^a,b   Kinnear, Craig J ^a,b   Niehaus, Dana J H ^b   Moolman Smook, Johanna C ^a   Lochner, Christine ^b   Knowles, James A ^c   Corfield, Valerie A ^a   Stein, Dan J ^b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Afrikaner; Association studies; Genetics; Obsessive compulsive disorder

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; RECEPTOR SUBUNIT; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR;

ALLELE; ARTICLE; CASE CONTROL STUDY; DOPAMINERGIC SYSTEM; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PROTEIN VARIANT; SEROTONINERGIC SYSTEM; STATISTICAL SIGNIFICANCE; VARIABLE NUMBER OF TANDEM REPEAT;

EID: 0037335412     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(02)00129-3     Document Type: Article

References (56)

1. Billett E.A., Richter M.A., Sam F., Swinson R.P., Dai X.Y., King N., Badri F., Sasaki T., Buchanan J.A., Kennedy J.L. Investigation of dopamine system genes in obsessive-compulsive disorder. Psychiatr. Genet. 8:1998;163-169.
2. Camarena B., Rinetti G., Cruz C., Gomez A., de la Fuente J.R., Nicolini H. Additional evidence that genetic variation of MAO-A gene supports a gender subtype in obsessive-compulsive disorder. Am. J. Med. Genet. 105:2001;279-282.
3. Cruz C., Camarena B., King N., Paez F., Sidenberg D., de la Fuente J.R., Nicolini H. Increased prevalence of the seven-repeat variant of the dopamine D4 receptor gene in patients with obsessive-compulsive disorder with tics. Neurosci. Lett. 231:1997;1-4.
4. de Jager T., Corbett C.H., Badenhorst J.C., Brink P.A., Corfield V.A. Evidence of a long QT founder gene with varying phenotypic expression in South African families. J. Med. Genet. 33:1996;567-573.
5. de la Chapelle A. Disease gene mapping in isolated human populations: the example of Finland. J. Med. Genet. 30:1993;857-865.
6. Delgado P.L., Moreno F.A. Different roles for serotonin in anti-obsessional drug action and the pathophysiology of obsessive-compulsive disorder. Br. J. Psychiatry. (Suppl.):1998;21-25.
7. Easterbrook P.J., Berlin J.A., Gopalan R., Matthews D.R. Publication bias in clinical research. Lancet. 337:1991;867-872.
8. el Mansari M., Bouchard C., Blier P. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder. Neuropsychopharmacology. 13:1995;117-127.
9. Enoch M.A., Kaye W.H., Rotondo A., Greenberg B.D., Murphy D.L., Goldman D. 5-HT2A promoter polymorphism -1438G/A, anorexia nervosa, and obsessive-compulsive disorder. Lancet. 351:1998;1785-1786.
10. Enoch M.A., Greenberg B.D., Murphy D.L., Goldman D. Sexually dimorphic relationship of a 5-HT2A promoter polymorphism with obsessive-compulsive disorder. Biol. Psychiatry. 49:2001;385-388.
11. Fog R. On stereotypy and catalepsy: studies on the effect of amphetamines and neuroleptics in rats. Acta Neurol. Scand. Suppl. 50:1972;3-66.
12. First M.B., Spizer R.L., Gibbon M., Williams J.B. Structured Clinical Interview for Axis I DSM-IV disorders. 1994;Paediatrics Research Department, New York State Psychiatric Institute.
13. Frisch A., Michaelovsky E., Rockah R., Amir I., Hermesh H., Laor N., Fuchs C., Zohar J., Lerer B., Buniak S.F., Landa S., Poyurovsky M., Shapira B., Weizman R. Association between obsessive-compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways. Eur. Neuropsychopharmacol. 10:2000;205-209.
14. Goodman W.K., McDougle C.J., Price L.H., Riddle M.A., Pauls D.L., Leckman J.F. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J. Clin. Psychiatry. 51:(Suppl.):1990;36-43.
15. Gordon D., Simonic I., Ott J. Significant evidence for linkage disequilibrium over a 5-cM region among Afrikaners. Genomics. 66:2000;87-92.
16. Greenberg B.D., Benjamin J., Martin J.D., Keuler D., Huang S.J., Altemus M., Murphy D.L. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients. Psychopharmacol. (Berl.). 140:1998;434-444.
17. Greist J.H., Jefferson J.W., Kobak K.A., Katzelnick D.J., Serlin R.C. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch. Gen. Psychiatry. 52:1995;53-60.
18. Heinz A., Goldman D., Jones D.W., Palmour R., Hommer D., Gorey J.G., Lee K.S., Linnoila M., Weinberger D.R. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology. 22:2000;133-139.
19. Hollander E., DeCaria C.M., Nitescu A., Gully R., Suckow R.F., Cooper T.B., Gorman J.M., Klein D.F., Liebowitz M.R. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch. Gen. Psychiatry. 49:1992;21-28.
20. Hotamisligil G.S., Breakefield X.O. Human monoamine oxidase A gene determines levels of enzyme activity. Am. J. Hum. Genet. 49:1991;383-392.
21. Jenike M.A. An update on obsessive-compulsive disorder. Bull. Menninger Clin. 65:2001;4-25.
22. Karayiorgou M., Altemus M., Galke B.L., Goldman D., Murphy D.L., Ott J., Gogos J.A. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc. Natl. Acad. Sci. USA. 94:1997;4572-4575.
23. Karayiorgou M., Sobin C., Blundell M.L., Galke B.L., Malinova L., Goldberg P., Ott J., Gogos J.A. Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder. Biol. Psychiatry. 45:1999;1178-1189.
24. Koran L.M., Pallanti S., Quercioli L. Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. Eur. Neuropsychopharmacol. 11:2001;169-172.
25. LaHoste G.J., Swanson J.M., Wigal S.B., Glabe C., Wigal T., King N., Kennedy J.L. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol. Psychiatry. 1:1996;121-124.
26. Lichter J.B., Barr C.L., Kennedy J.L., Van Tol H.H., Kidd K.K., Livak K.J. A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum. Mol. Genet. 2:1993;767-773.
27. Liebowitz M.R., Hollander E., Schneier F., Campeas R., Welkowitz L., Hatterer J., Fallon B. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatr. Scand. Suppl. 360:1990;29-34.
28. McDougle C.J., Goodman W.K., Leckman J.F., Lee N.C., Heninger G.R., Price L.H. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch. Gen. Psychiatry. 51:1994;302-308.
29. McDougle C.J., Epperson C.N., Pelton G.H., Wasylink S., Price L.H. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch. Gen. Psychiatry. 57:2000;794-801.
30. Moolman-Smook J.C., De Lange W.J., Bruwer E.C., Brink P.A., Corfield V.A. The origins of hypertrophic cardiomyopathy-causing mutations in two South African subpopulations: a unique profile of both independent and founder events. Am. J. Hum. Genet. 65:1999;1308-1320.
31. Mundo E., Richter M.A., Sam F., Macciardi F., Kennedy J.L. Is the 5-HT(1Dbeta) receptor gene implicated in the pathogenesis of obsessive-compulsive disorder? Am. J. Psychiatry. 157:2000;1160-1161.
32. Nicolini H., Cruz C., Camarena B., Orozco B., Kennedy J.L., King N., Weissbecker K., de la Fuente J.R., Sidenberg D. DRD2, DRD3 and 5HT2A receptor genes polymorphisms in obsessive-compulsive disorder. Mol. Psychiatry. 1:1996;461-465.
33. Niehaus D.J., Kinnear C.J., Corfield V.A., du Toit P.L., Van Kradenburg J., Moolman-Smook J.C., Weyers J.B., Potgieter A., Seedat S., Emsley R.A., Knowles J.A., Brink P.A., Stein D.J. Association between a catechol-O-methyltransferase polymorphism and obsessive-compulsive disorder in the Afrikaner population. J. Affect. Disord. 65:2001;61-65.
34. Nothen M.M., Propping P., Fimmers R. Association versus linkage studies in psychosis genetics. J. Med. Genet. 30:1993;634-637.
35. Ohara K., Xie D.W., Ishigaki T., Deng Z.L., Nakamura Y., Suzuki Y., Miyasato K., Ohara K. The genes encoding the 5HT1D alpha and 5HT1D beta receptors are unchanged in patients with panic disorder. Biol. Psychiatry. 39:1996;5-10.
36. Pauls D.L., Towbin K.E., Leckman J.F., Zahner G.E., Cohen D.J. Gilles de la Tourette's syndrome and obsessive-compulsive disorder. Evidence supporting a genetic relationship. Arch. Gen. Psychiatry. 43:1986;1180-1182.
37. Pauls D.L., Raymond C.L., Stevenson J.M., Leckman J.F. A family study of Gilles de la Tourette syndrome. Am. J. Hum. Genet. 48:1991;154-163.
38. Pian K.L., Westenberg H.G., van Megen H.J., den Boer J.A. Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder. Psychopharmacol. (Berl.). 140:1998;365-370.
39. Pitman R.K., Green R.C., Jenike M.A., Mesulam M.M. Clinical comparison of Tourette's disorder and obsessive-compulsive disorder. Am. J. Psychiatry. 144:1987;1166-1171.
40. Schindler K.M., Richter M.A., Kennedy J.L., Pato M.T., Pato C.N. Association between homozygosity at the COMT gene locus and obsessive compulsive disorder. Am. J. Med. Genet. 96:2000;721-724.
41. Service S.K., Ophoff R.A., Freimer N.B. The genome-wide distribution of background linkage disequilibrium in a population isolate. Hum. Mol. Genet. 10:2001;545-551.
42. Sheffield V.C., Stone E.M., Carmi R. Use of isolated inbred human populations for identification of disease genes. Trends Genet. 14:1998;391-396.
43. Sidenberg D.G., King N., Kennedy J.L. Analysis of new D4 dopamine receptor (DRD4) coding region variants and TH microsatellite in the Old Order Amish family (OOA110). Psychiatr. Genet. 4:(2):1994;95-99.
44. Souery D., Rivelli S.K., Mendlewicz J. Molecular genetic and family studies in affective disorders: state of the art. J. Affect. Disord. 62:2001;45-55.
45. Starfield M., Hennies H.C., Jung M., Jenkins T., Wienker T., Hull P., Spurdle A., Kuster W., Ramsay M., Reis A. Localization of the gene causing keratolytic winter erythema to chromosome 8p22-p23, and evidence for a founder effect in South African Afrikaans-speakers. Am. J. Hum. Genet. 61:1997;370-378.
46. Stein D.J., Spadaccini E., Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 10:1995;11-18.
47. Stein D.J., Van Heerden B., Wessels C.J., Van Kradenburg J., Warwick J., Wasserman H.J. Single photon emission computed tomography of the brain with Tc-99 m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor. Prog. Neuropsychopharmacol. Biol. Psychiatry. 23:1999;1079-1099.
48. Stern L., Zohar J., Cohen R., Sasson Y. Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT1D agonist sumatriptan. Eur. Neuropsychopharmacol. 8:1998;325-328.
49. Tiret L., Poirier Q., Nicaud V., Barbaux S., Herrmann S.M., Perret C., Raoux S., Francomme C., Lebard G., Tregouet D., Cambien F. Heterogeneity of linkage disequilibrium in human genes has implications for association studies of common diseases. Hum. Mol. Genet. 11:2002;419-429.
50. Vandenbergh D.J., Persico A.M., Hawkins A.L., Griffin C.A., Li X., Jabs E.W., Uhl G.R. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics. 14:1992;1104-1106.
51. Warren J.T. Jr., Peacock M.L., Rodriguez L.C., Fink J.K. An MspI polymorphism in the human serotonin gene (HTR2): detection by DGGE and FLP analysis. Hum. Mol. Genet. 2:1993;338.
52. Weissman M.M., Bland R.C., Canino G.J., Greenwald S., Hwu H.G., Lee C.K., Newman S.C., Oakley-Browne M.A., Rubio-Stipec M., Wickramaratne P.J. The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group. J. Clin. Psychiatry. 55:(Suppl.):1994;5-10.
53. Zavattari P., Deidda E., Whalen M., Lampis R., Mulargia A., Loddo M., Eaves I., Mastio G., Todd J.A., Cucca F. Major factors influencing linkage disequilibrium by analysis of different chromosome regions in distinct populations: demography, chromosome recombination frequency and selection. Hum. Mol. Genet. 9:2000;2947-2957.
54. Zohar J., Insel T.R. Drug treatment of obsessive-compulsive disorder. J. Affect. Disord. 13:1987;193-202.
55. Zohar J., Mueller E.A., Insel T.R., Zohar-Kadouch R.C., Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch. Gen. Psychiatry. 44:1987;946-951.
56. 1D involved in obsessive-compulsive disorder? Eur. Neuropsychol. 6:1996;54-55.